Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.

🧫 Experiment Protocol ClinicalAlzheimer's diseasehumanextracted

Fluid biomarker detection of phosphorylated tau (pT217Tau)

PRIMARY OUTCOME

LINKED HYPOTHESES

Source: pmid_40767321

🧫 Experiment Extras

PATHWAY

tau pathology

MARKET PRICE

$0.50

STATUS

extracted

Prediction Markets (1 direct, 0 via hypothesis — 1 total)